reports
- Jacob Mekhael
Merus Petosemtamab phase 2 mCRC results show high response rates
Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer De...
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Merus Announces Publication of an Abstract on Petosemtamab in Metastat...
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Bicloni...
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract ...
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Lewi
Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus to Present at the 2025 Wells Fargo Healthcare Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET. The webcast of the presentation will be contemporaneously ava...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt un...
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung – Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 % bei 43 auswertbaren Patienten und eine Gesamtüberlebensrate von 79 % nach 12 Monaten – Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln und Barmitteläquivalenten, einschließlich des erfolgreichen Börsengangs mit ei...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités - Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 % et un taux de survie globale de 79 % à 12 mois - D’après le plan d’exploitation actuel de la société, la trésorerie et les équivalents de trésorerie existants, notamment le produit brut de 345 millions de dollars réalisé à l’issue d’une offre publique réussie et les titres négociables devr...
Merus to Present at the Canaccord Genuity 45th Annual Growth Conferenc...
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET. The webcast of the presentation will be conte...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Merus Announces Financial Results for the Second Quarter 2025 and Prov...
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating plan, existing cash, cash equivalents, including successful public offering raising $345M gross proceeds, and marketable securities expected to fund Merus’ operations at least into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE...
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2016 Incentive Award Plan (the “Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Co...
Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt
Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, hat heute den Preis eines geplanten öffentlichen Zeichnungsangebots von 5.263.158 Stammaktien zu einem öffentlichen Angebotspreis von 57,00 USD je Aktie (die „Angebotsaktien“) bekanntgegebe...
Merus N.V. annonce la fixation du prix de l’offre publique d’actions o...
Merus N.V. annonce la fixation du prix de l’offre publique d’actions ordinaires UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus », la « Société », « nous » ou « notre/nos », une société spécialisée dans l’oncologie développant des anticorps multispécifiques pleine longueur innovants et des conjugués anticorps-médicaments appelés Biclonics®, Triclonics® et ADClonics®, fixe ce jour le prix de lancement de ses 5 263 158 actions ordinaires à 57,00 dollars chacune dans le cadre de son offre publique de souscri...
Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammakti...
Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, gab heute den Start eines geplanten öffentlichen Zeichnungsangebots seiner Stammaktien (die „Angebotsaktien“) bekannt. Alle Stammaktien werden von Merus angeboten. Darüber hinaus ...
Merus N.V. annonce une offre publique de souscription d’actions ordina...
Merus N.V. annonce une offre publique de souscription d’actions ordinaires UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants et des conjugués anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), a annoncé aujourd’hui le lancement d’une offre publique de souscription de ses actions ordinaires (les « Actions de l’offre »). Toutes les actions ordinaires sont proposées par Merus. E...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.